Mizuho Has Lowered Expectations for MiMedx Group (NASDAQ:MDXG) Stock Price

MiMedx Group (NASDAQ:MDXG) had its target price lowered by Mizuho from $12.00 to $10.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho’s price objective suggests a potential upside of 37.93% from the stock’s current price.

MDXG has been the subject of a number of other research reports. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research report on Monday. Wall Street Zen raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 2nd. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

MiMedx Group Stock Up 1.8%

Shares of NASDAQ:MDXG opened at $7.25 on Wednesday. The firm has a market capitalization of $1.07 billion, a PE ratio of 26.85 and a beta of 1.64. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. MiMedx Group has a 52-week low of $5.79 and a 52-week high of $9.71. The firm has a fifty day moving average of $7.00 and a 200 day moving average of $6.85.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%.The firm had revenue of $67.69 million for the quarter. As a group, research analysts anticipate that MiMedx Group will post 0.3 EPS for the current fiscal year.

Insider Buying and Selling

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 58,300 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total value of $432,586.00. Following the completion of the sale, the insider owned 236,982 shares in the company, valued at approximately $1,758,406.44. The trade was a 19.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Deutsche Bank AG boosted its position in MiMedx Group by 144.2% during the 1st quarter. Deutsche Bank AG now owns 321,296 shares of the company’s stock valued at $2,442,000 after buying an additional 189,750 shares during the period. Invesco Ltd. increased its position in shares of MiMedx Group by 34.6% in the first quarter. Invesco Ltd. now owns 76,123 shares of the company’s stock valued at $579,000 after acquiring an additional 19,558 shares during the period. Nuveen LLC bought a new position in shares of MiMedx Group during the first quarter valued at about $2,355,000. Russell Investments Group Ltd. raised its stake in shares of MiMedx Group by 262.5% during the first quarter. Russell Investments Group Ltd. now owns 26,114 shares of the company’s stock valued at $198,000 after acquiring an additional 18,911 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of MiMedx Group by 36.0% during the first quarter. American Century Companies Inc. now owns 270,808 shares of the company’s stock worth $2,058,000 after purchasing an additional 71,739 shares during the period. 79.15% of the stock is owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.